Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

被引：0
|
作者：
Ali Afshar-Oromieh
Uwe Haberkorn
Christian Zechmann
Thomas Armor
Walter Mier
Fabian Spohn
Nils Debus
Tim Holland-Letz
John Babich
Clemens Kratochwil
机构：
[1] Heidelberg University Hospital,Department of Nuclear Medicine
[2] German Cancer Research Center,Clinical Cooperation Unit Nuclear Medicine
[3] Progenics Pharmaceuticals,Department of Biostatistics
[4] Inc.,Division of Radiopharmaceutical Sciences, Department of Radiology
[5] German Cancer Research Center,Citigroup Biomedical Imaging Center
[6] Weill Cornell Medicine,Meyer Cancer Center
[7] Weill Cornell Medicine,undefined
[8] Weill Cornell Medicine,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Prostate cancer; PSMA; Prostate-specific membrane antigen; Endoradiotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：950 / 959
页数：9
相关论文
共 50 条
  • [41] 177Lutetium PSMA radioligand therapy in prostate cancer
    Vis A.N.
    Jansen B.H.E.
    Bodar Y.J.L.
    Nieuwenhuijzen J.A.
    Hendrikse H.N.
    Oprea-Lager D.E.
    Tijdschrift voor Urologie, 2020, 10 (4) : 60 - 65
  • [42] Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer Oncological Outcomes and Toxicity Profile
    Demirkol, Mehmet Onur
    Esen, Baris
    Seymen, Huelya
    Sen, Melis
    Ucar, Burcu
    Kurtuldu, Sevgilay
    Mandel, Nil Molinas
    Bavbek, Sevil
    Falay, Okan
    Tilki, Derya
    Esen, Tarik
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : E564 - E569
  • [43] Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
    Ng, Thomas S. C.
    Gao, Xin
    Salari, Keyan
    Zlatev, Dimitar V.
    Heidari, Pedram
    Kamran, Sophia C.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [45] Lu-PSMA Radioligand Therapy for advanced Prostate Cancer
    Derlin, T.
    RADIOLOGE, 2017, 57 (12): : 1001 - 1003
  • [46] Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
    Daria Arbuznikova
    Matthias Eder
    Anca-Ligia Grosu
    Philipp T. Meyer
    Christian Gratzke
    Constantinos Zamboglou
    Ann-Christin Eder
    Current Oncology Reports, 2023, 25 : 1363 - 1374
  • [47] A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castrationresistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
    Yu, Evan Y.
    Laidley, David
    Pouliot, Frederic
    Probst, Stephan
    Saad, Fred
    Sabbagh, Robert
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [49] Rechallenge 177Lu-PSMA radioligand therapy: First assessment in patients with metastatic prostate cancer
    Gafita, A.
    Eiber, M.
    Rauscher, I.
    Retz, M.
    Knorr, K.
    Heck, M.
    Gschwend, J.
    Schwaiger, M.
    Weber, W.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S587 - S587
  • [50] PSMA radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617
    Kulkarni, Harshad
    Singh, Aviral
    Niepsch, Karin
    Schuchardt, Christiane
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345